

Preliminary Programme

European Congress of
Clinical Microbiology
and Infectious Diseases

Lisbon, Portugal
23 – 26 April 2022

ECCMID



32nd

Disclaimer & Dates

Disclaimer

The following ECCMID 2022 scientific programme is preliminary only, and does not represent the entirety of the ECCMID invited programme. Speakers and chairpersons will be added to sessions as they are confirmed.

Industry sessions from industry partners will also be published once confirmed.

The ECCMID 2022 scientific programme is expected to be finalised in March of 2022.

Present your research and be part of ECCMID!

ECCMID has become one of the most comprehensive and influential congresses in the field of infection and an exciting networking place bringing together >14,000 colleagues from all over the world. Share and discuss your research with colleagues from around the world.

Abstract submission

Regular abstracts can be submitted from 18 October 2021 to 24 November 2021.
Latebreaker abstracts submission dates will be communicated in January 2022.

Registration

Early Bird fee	until 2 February 2022
Regular fee	from 3 February to 16 March 2022
Late fee	from 17 March 2022
Free admission	ECCMID 2022 registered participants

Preliminary Programme

Keynote Lectures

Keynote lecture



Clinical research in infectious endocarditis: past, present, and future **Jose María Miró (Barcelona, Spain)**

Dr. José M. Miró has been Senior Consultant of Infectious Diseases at the Hospital Clinic – IDIBAPS of Barcelona since 2001. He is Professor of Medicine at the University of Barcelona, IDIBAPS investigator and Director of the Master of HIV/AIDS of the University of Barcelona. His research fields are focused on infective endocarditis (including the experimental model) and HIV/AIDS (Cohort studies, primary HIV-1 infection, opportunistic Infections, late presenters, solid organ transplantation in HIV-1 infection, COVID-19). He has published more than 850 articles in peer-review journals (h-index 76). He was President of GESIDA (1998-99), the Catalan Society of Infectious Diseases and Clinical Microbiology (SCMIMC, 2005-07), the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC, 2013-15) and currently is President of the International Society of Cardiovascular Infectious Diseases (ISCVI, 2019-23).

Keynote lecture



Harnessing deep learning and synthetic biology to fight pathogens **James Collins (Boston, United States)**

Jim Collins is the Termeer Professor of Medical Engineering & Science and Professor of Biological Engineering at MIT, as well as a Member of the Harvard-MIT Health Sciences & Technology Faculty. He is also a Core Founding Faculty member of the Wyss Institute for Biologically Inspired Engineering at Harvard University, and an Institute Member of the Broad Institute of MIT and Harvard. He is one of the founders of the field of synthetic biology, and his research group is currently focused on using synthetic biology to create next-generation diagnostics and therapeutics. Prof. Collins' patented technologies have been licensed by over 25 biotech, pharma and medical device companies, and he has co-founded a number of companies, including Synlogic, Senti Biosciences, Sherlock Biosciences and Cellarity, as well as Phare Bio, a non-profit focused on AI-driven antibiotic discovery. He has received numerous awards and honors, including a Rhodes Scholarship and a MacArthur "Genius" Award, and he is an elected member of all three national academies - the National Academy of Sciences, the National Academy of Engineering, and the National Academy of Medicine.

Co-organised with: ESCMID Study Group for Biofilms (ESGB)

Keynote lecture



Future threats from coronaviruses **Malik Peiris (Hong Kong, Hong Kong)**

Malik Peiris is currently the Professor and Chair in Virology at the School of Public Health, The University of Hong Kong. His research focuses on the virology, ecology, pathogenesis and epidemiology of influenza, coronaviruses, and other emerging respiratory viral infections. He has a particular interest in emerging viral infections at the animal-human interface and in the application of the "One Health" approach to emerging infectious diseases. In 2003, he played a key role in the discovery that a novel coronavirus was the cause of SARS and understanding its pathogenesis and control. In collaboration with his colleagues at the School of Public Health, his research has elucidated the emergence, transmission, and pathogenesis of avian influenza viruses H5N1, H9N2, H7N9, and the pandemic H1N1 virus of 2009 and, more recently, of the MERS coronavirus. Prof. Peiris was awarded the Silver Bahunia Star of the HKSAR in 2008, and was elected a the Fellow of the Royal Society of London in 2006 and as the Foreign Member of the US National Academy of Science in 2017.

Keynote lecture



Advances in clinical antibacterial resistance research **Evelina Tacconelli (Verona, Italy)**

Evelina Tacconelli is the Director of the Infectious Diseases Section at Verona University Hospital, Italy, and serves as the Senior Consultant on Antimicrobial Resistance at the Department of Internal Medicine, DZIF Clinical Research Unit at the University of Tübingen, Germany. Previously, she coordinated the WHO priority list of antibiotic resistant bacteria for the research and development of new effective antibiotics as well as the WHO project on limitations of estimates of the burden of antibiotic resistant infections within the GLASS (Global Surveillance of Resistant Severe Infections) project. Prof. Tacconelli is a Chair of the European Committee for Infection Control (EUCIC), WHO and ECDC (European Centre for Disease Prevention and Control) consultant for infection control and antimicrobial stewardship. She currently serves as a coordinator of the Italian working group on optimising antibiotics' prescriptions for AIFA, the Italian Medicine Agency. She is a chief author of the ESCMID guidelines for the management and control of infections due to MDR-Gram negatives and the EUCIC guidelines for the decolonisation of MDR-gram negatives and surgical prophylaxis in colonised patients. For years she has participated and coordinated the European projects and networks focused on antimicrobial resistance. She is a leader and coordinator of ORCHESTRA - Connecting European Cohorts to Increase Common and Effective Response to SARS-CoV-2 Pandemic, a research project funded by the European Union's Horizon 2020 Programme aiming at applying an innovative approach to fight against COVID-19 and improve the management of future pandemics.

Preliminary Programme

Keynote Lectures

Keynote lecture



**Pathogens and the microbiome:
antibiotics at the crossroads**
Martin Blaser (New Jersey, United States)

Martin J. Blaser holds the Henry Rutgers Chair of the Human Microbiome at Rutgers University, and serves as Director of the Center for Advanced Biotechnology and Medicine. Previously, he served as Chair of the Department of Medicine at New York University. A physician and microbiologist, Dr. Blaser has been studying the relationships we have with the human microbiome, the bacteria that live in us. Over the last 20 years, he has also been actively studying the relationship of the human microbiome with both health and important diseases including asthma, obesity, diabetes, and cancer. Dr. Blaser has been the advisor to many students, post-doctoral fellows, and faculty. He has served as President of the Infectious Diseases Society of America, Chair of the Board of Scientific Counselors of the National Cancer Institute, and Chair of the Advisory Board for Clinical Research of the NIH. He currently serves as Chair of the Presidential Advisory Council for Combatting Antibiotic Resistant Bacteria (PACCARB). He was elected to the National Academy of Medicine and the American Academy for Arts and Sciences. He has authored over 630 original scientific articles, and holds 24 U.S. patents, and he also wrote *Missing Microbes*, a book targeted to general audiences, now translated into 20 languages.

Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI) and American Society of Microbiology (ASM)

Keynote lecture



**Never let an outbreak go to waste: how COVID-19
has changed hospital epidemiology and infection
prevention and control**
Alison Holmes (London, United Kingdom)

Alison Holmes is the Professor of Infectious Diseases and the Director of the NIHR Health Protection Research Unit in Healthcare Associated Infections and AMR and the Centre for Antimicrobial Optimisation (CAMO), at Imperial College London. She is also the current President of the International Society for Infectious Diseases. Prof. Holmes is an NIHR Senior Investigator and has a longstanding career in the NHS. She serves on WHO Expert groups related to antimicrobial use, AMR, infection prevention, sepsis, and COVID-19. She leads a large international, multidisciplinary infectious disease research programme, including collaborative programmes funded by NIHR, ESRC, UKRI and Wellcome Trust on the improved management and prevention of infections, particularly focusing on the optimising of antimicrobial use and addressing antimicrobial resistance through the integration of social sciences, the application of innovative approaches and technologies and the development of precision medicine.

Co-organised with: European Committee on Infection Control (EUCIC) Steering Committee

Preliminary Programme

2-hour Symposia

2-hour Symposium

Update on the WHO strategy to eliminate viral hepatitis

The 2021 WHO global progress report

TBA

Monitoring progress towards the elimination targets in EU/EEA countries

Erika Duffell (Solna, Sweden)

Inequalities among key populations

Nurcan Baykam (Coru, Turkey)

TBA

HCV elimination in Egypt

Manal Elsayed (Cairo, Egypt)

Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH)

2-hour Symposium

Past, present, and future of pandemics: preparedness and first defense

Influenza and the COVID-19 pandemic

Nicola Petrosillo (Rome, Italy)

Viral poliomyelitis: acute flaccid paralysis

TBA

Ebola and other haemorrhagic fevers

Eskild Petersen (Aabyhøj, Denmark)

What we learnt from COVID-19 for Crimean-Congo Haemorrhagic Fever?

Önder Ergönül (Istanbul, Turkey)

Co-organised with: ESCMID Study Group for Public Health Microbiology (ESGPHM)

2-hour Symposium

Updates on HIV treatment and prevention

Progress toward reaching HIV prevention and treatment targets in Europe

Teymur Noori (Stockholm, Sweden)

HIV treatment: which are the drugs?

Marta Vasylyev (Lviv, Ukraine)

HIV and the cure: what is new in the HIV the vaccine research?

Simona Ruta (Bucharest, Romania)

Patients' perspectives on PrEP

TBA

Co-organised with: European AIDS Clinical Society (EACS)

2-hour Symposium

HIV and the reservoir: what is new?

Exploring HIV cure in a resource-limited setting

Thumbi Ndung'u (Durban, South Africa)

New ways to manipulate the reservoir

Tokameh Mahmoudi (Rotterdam, Netherlands)

New immunological insights for destroying the reservoir

TBA

What is new in clinical trials?

Thom Rasmussen (Copenhagen, Denmark)

2-hour Symposium

Sepsis 2022: prevent it, spot it, treat it, beat it

Sepsis immunity: new insights from multi-omics

TBA

What's hot in sepsis diagnostics?

Alessandra Bandera (Milano, Italy)

Long-term consequences of sepsis

Manu Shankar-Hari (London, United Kingdom)

Beyond antibiotics: improving care of patients with BSI and sepsis

Jordi Rello (Barcelona, Spain)

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), International Sepsis Forum (ISF), International Immunocompromised Host Society (ICHS), and ESCMID Study Group for Infections in Compromised Hosts (ESGICH)

2-hour Symposium

Let's not forget about atypical bacterial respiratory pathogens

The re-emergence of pertussis

TBA

Diagnostic improvements in *Legionella*

Sophie Jarraud (Lyon, France)

Recent developments in *Mycoplasma*

Victoria Chalker (London, United Kingdom)

Recent developments in *Chlamydia*

Gilbert Greub (Lausanne, Switzerland)

Co-organised with: ESCMID Study Group for Mycoplasma and Chlamydia Infections (ESGMAC) and ESCMID Study Group for Legionella Infections (ESGLI)

Preliminary Programme

2-hour Symposia

2-hour Symposium

Molecular-guided therapy for sexually transmitted infections (STIs)

Molecular-guided therapy for *Mycoplasma genitalium*
Catriona Bradshaw (Melbourne, Australia)
Molecular-guided therapy for gonorrhoea
Magnus Unemo (Örebro, Sweden)
Molecular-guided therapy for *Chlamydia trachomatis*
Cécile Bébéar (Bordeaux, France)
STIs in a sexual assault: sampling guidelines
Amparo Fernandez-Rodriguez (Madrid, Spain)

Co-organised with: ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), ESCMID Study Group for Mycoplasma and Chlamydia Infections (ESGMAC), and ESCMID Study Group for Forensic and Postmortem Microbiology (ESGFOR)

2-hour Symposium

Severe skin and soft tissue infection

Pathology of toxins
Francois Vandenesch (Lyon, France)
Antimicrobial therapy
Kristina Öbrink-Hansen (Aarhus, Denmark)
Surgical evaluation and intervention
Christian Eckmann (Hannover, Germany)
Prospects for immunological interventions: IVIG-therapy
Anna Norrby-Teglund (Huddinge, Sweden)

Co-organised with: ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS), ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), and ESCMID Study Group for Critically Ill Patients (ESGCIP)

2-hour Symposium

Genomics underpin the clinical and public health management of tuberculosis

Understanding TB pathogenicity and host interactions using genomic approaches
Stefan Niemann (Borstel, Germany)
Implementing genomics in TB management: the European experience
Paolo Miotto (Milano, Italy)
Integrating genomics into TB management in an African setting
TBA
New tools for genomic prediction and mapping of resistance in TB
Timothy Walker (Ho Chi Minh City, Viet Nam)

2-hour Symposium

ESCMID Guidelines for the treatment of infections caused by multidrug-resistant Gram-negatives: a case-based approach

Cases of cephalosporin-resistant Enterobacterales
Thomas Tängdén (Uppsala, Sweden)
Cases of carbapenem-resistant Enterobacterales
Pilar Retamar Gentil (Sevilla, Spain)
Cases of multidrug-resistant *P. aeruginosa*
Robert A. Bonomo (Cleveland, United States)
Cases of multidrug-resistant *A. baumannii*
Elena Carrara (Verona, Italy)

2-hour Symposium

New developments in antimicrobial resistance and virulence of anaerobic pathogens

EUCAST recommended method for antimicrobial susceptibility testing of anaerobic bacteria
Erika Matuschek (Växjö, Sweden)
Carbapenem and metronidazole resistance mechanisms of *Bacteroides*
Jozsef Soki (Szeged, Hungary)
***Bacteroides fragilis*: a tale of two habitats**
Sheila Patrick (Edinburgh, United Kingdom)
How do *Bacteroides* exert their useful activities in the human gastrointestinal tract?
TBA

Co-organised with: ESCMID Study Group for Anaerobic Infections (ESGAI)

2-hour Symposium

The role of genomics in AMR surveillance

Genomics for AMR surveillance in invasive bacterial infections: add-on or a leapfrog technology?
TBA
Genomic surveillance and the detection of new and emerging AMR mechanisms
Senjuti Saha / Dhaka, Bangladesh)
Genomic surveillance and microevolutionary changes with new resistance development in MDR *M. tuberculosis*
Josefina Campos (Buenos Aires, Argentina)
Emergence of a transferrable ceftazidime-avibactam resistance in blaKPC-producing *Klebsiella pneumoniae*
TBA

Preliminary Programme

2-hour Symposia

2-hour Symposium

Plasmid curing for combating antibiotic resistance

Plasmids: their role in antibiotic resistance

Monika Dolejska (Brno, Czech Republic)

Anti-plasmid and plasmid curing compounds

Michelle Buckner (Birmingham, United Kingdom)

CRISPR/Cas systems for plasmid curing

TBA

Toxin-antitoxin systems and plasmid curing

Alessandra Carattoli (Rome, Italy)

2-hour Symposium

Bronchiectasis: microbes, pathogenesis, treatment

The microbiome and bronchiectasis

Sanjay Haresh (Singapore, Singapore)

Inflammation and bronchiectasis

James D. Chalmers (Dundee, United Kingdom)

New approaches in the management of bronchiectasis

Stefano Aliberti (Milano, Italy)

Current and advanced imaging techniques in bronchiectasis

Efthymia Alexopoulou (Athens, Greece)

Co-organised with: European Respiratory Society (ERS)

2-hour Symposium

Long-read sequencing: from benchtop to bedside

Characterising pathogens in respiratory samples using rapid metagenomic sequencing

Themoula Charalampous (London, United Kingdom)

Using metagenomics to trace antimicrobial resistance and pathogens along the food chain

Thi Thuy Do (Maynooth, Ireland)

Phylogenetic modelling of bacterial outbreaks using nanopore sequencing

TBA

Quality assessment for clinical shotgun metagenomics

TBA

Co-organised with: ESCMID Study Group for

Epidemiological Markers (ESGEM) and ESCMID Study

Group for Genomic and Molecular Diagnostics (ESGMD)

2-hour Symposium

The dark side of Gram-negative respiratory infections in the ICU

What makes a patient vulnerable to infections by non-fermenters

TBA

Factors contributing to the persistence of pathogenic *Acinetobacter* in the hospital setting

Paolo Visca (Rome, Italy)

The microbiology and pathogenesis of *Stenotrophomonas maltophilia* infection

Joanna Brooke (Chicago, United States)

How to diagnose and treat infection with non-fermenters in the ICU

Adrien Bouglé (Paris, France)

2-hour Symposium

Impact of rapid diagnostics for community-acquired acute respiratory tract infections (CA-ARTI) on antibiotic stewardship

What is diagnostic stewardship and why should we care?

Bhanu Sinha (Groningen, Netherlands)

Consensus about the use of rapid diagnostics for the management of CA-ARTI

Eva Polverino (Barcelona, Spain)

Point-of-care testing and antibiotic prescribing for CA-ARTI in primary care: an 18 countries audit

Alike van der Velden (Utrecht, Netherlands)

Rapid diagnosis of CA-ARTI in the ambulatory care or in the emergency room: Are there differences?

TBA

Co-organised with: VALUE-Dx and European Respiratory Society (ERS)

2-hour Symposium

New antibiotics in the pipeline – where and what did we get?

Selected natural product- and pathoblocker-based approaches for combating Gram-negatives

Rolf Müller (Saarbrücken, Germany)

New antibiotics against Gram-negatives in the clinic

Marc J.M. Bonten (Utrecht, Netherlands)

New drugs against Gram-positives: preclinical and clinical landscape

Warren Rose (Madison, United States)

Stewardship approaches for new antibiotics

Pilar Retamar (Sevilla, Spain)

Preliminary Programme

2-hour Symposia

2-hour Symposium

Making decisions on antibiotic therapy in difficult situations

Streamlining empirical drugs when aetiology is unclear: is it possible?

Vera Vlahovic-Palcevski (Rijeka, Croatia)

Stopping therapy in doubtful situations

Jose Molina (Seville, Spain)

Avoiding combinations in severe infections and when XDR organisms are involved

Felipe Tuon (Curitiba, Brazil)

Dosing optimisation in real life - with which drugs, when, and how?

Birgit Koch (Rotterdam, Netherlands)

2-hour Symposium

New insights into phages: current challenges and future developments

Preparation standards for personalised phage therapy

Saija Kiljunen (Helsinki, Finland)

Phage biobanks: current challenges and future perspectives

TBA

Clinical trials with phages: design challenges and regulatory issues

Shawna McCallin (Zurich, Switzerland)

Clinical evidence for the efficacy of phages (so far)

Tristan Ferry (Lyon, France)

Co-organised with: ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA)

2-hour Symposium

Fungal infections from head to toe

Emerging treatment failure in dermatophytosis: genotyping and resistance testing of the *T. mentagrophytes* species complex

Philipp Bosshard (Zurich, Switzerland)

Update on Tinea capitis: epidemiology, symptoms, and treatment

Pietro Nenoff (Mölbis, Germany)

Update on diagnosis and treatment of recurrent vulvovaginal candidiasis

Riina Richardson (Manchester, United Kingdom)

The role of *Malassezia* in health and disease

Ditte Marie Saunte (Roskilde, Denmark)

Co-organised with: ESCMID Fungal Infection Study Group (EFISG)

2-hour Symposium

Travellers and migrants on the move again

Latent tuberculosis in migrants and travellers during COVID times

TBA

Update on malaria in migrants and travellers

George Akpede (Ekpoma, Nigeria)

How to manage nitroimidazole-refractory Giardiasis

TBA

Importation of MDR bacteria after hospitalisation abroad

Mikael Kajova (Helsinki, Finland)

Co-organised with: ESCMID Study Group for Infections in Travellers and Migrants (ESGITM)

2-hour Symposium

Different perspectives on infectious diseases diagnostics in LMICs

Overview of The Lancet Commission on Diagnostics

Mikashmi Kohli (Geneva, Switzerland)

Developing a national essential diagnostics list

Kamini Walia (New Delhi)

Current diagnostic capacities and the impact of COVID-19 in LMICs

Adeola Fowotade (Ibadan, Nigeria)

Review of the contribution of mobile laboratories in the response to outbreaks of VHFs and the COVID-19 pandemic

Sophie Duraffour (Hamburg, Germany)

Co-organised with: Lancet Commission on Diagnostics

2-hour Symposium

Unveiling the mysteries of FMT efficacy

Intestinal bile acids from faecal filtrate?

Roman A. Melnyk (Toronto, Canada)

Which genera of bacteria?

Surbhi Malhotra-Kumar (Antwerp, Belgium)

From the bacteriophages?

Siew Ng (Hong Kong, Hong Kong)

Beyond our gut microbiota!

TBA

Preliminary Programme

2-hour Symposia

2-hour Symposium

Genomics for hospital infection control

Application of genomics to investigate hospital outbreaks and inform infection control in a sub-Saharan African setting

Uduak Okomo (Fajara, Gambia)

Optimising genomic approaches for surveillance of multidrug resistant pathogens

Claire Gorrie (Melbourne, Australia)

Mapping the resistome in the hospital environment and implications for infection prevention

Niranjan Nagarajan (Singapore, Singapore)

Genomic investigation of drug resistant Gram-negatives in a Nepalese hospital

Abhilasha Karkey (Kathmandu, Nepal)

2-hour Symposium

Vaccinated or non-vaccinated: patients are not healthcare workers, and the flu is not COVID-19

How vaccines help healthcare workers to stay safe

Martin Kiernan (Lancashire, United Kingdom)

COVID-19 vaccine revisited: how to handle unvaccinated, poorly vaccinated, or immunosuppressed patients

Hilary Humphreys (Dublin, Ireland)

The triangle of personal protective equipment, vaccination, and screening make our hospitals safe

Nico Tom Mutters (Bonn, Germany)

Protecting the immunocompromised healthcare worker

Gabriel Birgand (Nantes, France)

Co-organised with: European Committee on Infection Control (EUCIC) Steering Committee

2-hour Symposium

Supporting evidence in infection prevention and control: 2022 ESCMID guidelines

Surgical prophylaxis in patients colonised with multidrug resistant Gram-negatives

Evelina Tacconelli (Verona, Italy)

Surgical prophylaxis in patients colonised with multidrug resistant Gram-positives

TBA

Screening procedures in healthcare workers and patients during the COVID-pandemic

Anders Johansson (Umea, Sweden)

Preventing transmission of multidrug resistant Gram-negatives in hospitalised patients

Nico Tom Mutters (Bonn, Germany)

Co-organised with: European Committee on Infection Control (EUCIC) Steering Committee

2-hour Symposium

Pathogen competition and co-evolution in the microbiome

Bacterial competition in the nasal microbiome

Andreas Peschel (Tuebingen, Germany)

Type VII secretion and death of co-colonisers

Tracy Palmer (Newcastle, United Kingdom)

Within population diversification in the host

TBA

Bacterial microcompartments and their role in pathogenicity

TBA

Co-organised with: ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)

2-hour Symposium

Innovative diagnostics in biofilm-associated infections

Biofilm viability checker

Thomas Bjarnsholt (Copenhagen, Denmark)

'Biofilm staging': at the interface of microbiology, pathology, and molecular biology

Annette Møter (Berlin, Germany)

Biosensors for the diagnosis of biofilm infections

Agneta Richter-Dahlfors (Stockholm, Sweden)

Managing complex biofilm-associated infections in the clinical microbiology lab

Craig Williams (Lancaster, United Kingdom)

Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Study Group for Host and Microbiota Interaction (ESGHMI), and ESCMID Study Group for Implant-Associated Infections (ESGII)

2-hour Symposium

Gut reaction: the connection between biofilms and disease

Bacterial biofilms and toxins: a perfect storm for colon cancer

Julia Drewes (Baltimore, United States)

Bacterial biofilms in colorectal cancer initiation and progression

TBA

RNA landscape of emerging cancer associated microbes

TBA

Gastrointestinal biofilms in health and disease

Nathalie Vergnolle (Paris, France)

Preliminary Programme

2-hour Symposia

2-hour Symposium

Genomic surveillance to inform development and implementation of anti-bacterial vaccines

Genomic tracking of *Bordetella pertussis* antigenic variant emergence in relation to diverse vaccine compositions

Sylvain Brisse (Paris, France)

Genomic surveillance for enteric fever in the early phase of new vaccine rollout

Firdausi Qadri (Dhaka, Bangladesh)

Using genomics to tailor meningococcal vaccine choice

Charlene Rodrigues (Oxford, United Kingdom)

Genomic surveillance and seroepidemiology of *Klebsiella pneumoniae*

Kelly Wyres (Clayton, Australia)

2-hour Symposium

Infections in patients receiving new immunomodulatory therapies

Patients receiving immune check-point inhibitors

Gil Redelman-Sidi (New York, United States)

Patients receiving CAR-T therapy

Andrea Henden (Brisbane, Australia)

Non-neutropaenic infection associated risk in patients with haematological malignancies

Monica Slavin (Melbourne, Australia)

Patients receiving therapy for systemic or organ-specific autoimmune diseases

TBA

2-hour Symposium

Challenges and opportunities in CM/ID training and practice

How to excel and become a leader in CM, ID, or IC?

Truls Leegaard (Lørenskog, Norway)

Self-care, mental health, and work-life balance

TBA

Practising clinical microbiology in low resource settings

TBA

Practising infectious diseases in low resource settings

Sipho Dlamini (Cape Town, South Africa)

Co-organised with: Professional Affairs Subcommittee and Trainee Association of ESCMID (TAE) Steering Committee

2-hour Symposium

Host and viral factors in COVID-19, what makes us sick?

Host factors for disease severity of COVID-19

TBA

The interplay between host and viral factors in the evolving COVID-19 pandemic

Marion Koopmans (Rotterdam, Netherlands)

Studying T-cell response after vaccination in COVID-19 transplant recipients

Coretta Van Leer-Buter (Groningen, Netherlands)

Genetic variants in the human population driving severe COVID-19

Alessandra Renieri (Siena, Italy)

Co-organised with: UEMS Section of Infectious Diseases and ESCMID Study Group for Infections in the Elderly (ESGIE)

2-hour Symposium

COVID-19: vaccinating the whole world?

Challenges to reach everyone on earth

TBA

COVID-19 vaccination roll-out: equal access to COVID-19 vaccines and vaccinating hard-to-reach populations

Jose Tuells (Alicante, Spain)

COVID-19 vaccines acceptance and hesitancy

Marco Safadi (Sao Paulo, Brazil)

Rethinking the ethics of vaccination and use of facemasks: balancing public good with human rights considerations

Raquel Duarte (Porto, Portugal)

Co-organised with: Professional Affairs Subcommittee (PAS), ESCMID Vaccine Study Group (EVASG) and International Affairs and World Association for Infectious Diseases and Immunological Disorders (Waidid)

Preliminary Programme

1-hour Symposia

1-hour Symposium

Respiratory viral infections in hospital settings

Respiratory virus infections in ICU patients besides SARS-CoV-2: what matters?

Ignacio Martin-Loeches (Dublin, Ireland)

Guidelines for diagnosis of COVID-19 and influenza

Barbara Rath (Banancon, France)

Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV) and ESCMID Study Group for Critically Ill Patients (ESGCIP)

1-hour Symposium

How to manage severe VHF in resource-limited settings

Determinants of severe VHF outcome and the need for dedicated critical care centres

TBA

How to manage severe VHF: case studies of Ebola and Lassa fever

Nnennaya Ajayi (Abakaliki, Nigeria)

1-hour Symposium

Hepatitis E

Transfusion associated fulminant HEV infection

Heli Harvala-Simmonds (Colindale, United Kingdom)

Prospects for an HEV vaccine

TBA

Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH) and ESCMID Vaccine Study Group (EVASG)

1-hour Symposium

The changing epidemiology of West Nile virus in Europe

Epidemiological trends of West Nile virus in Western Europe

Chantal Reusken (Bilthoven, Netherlands)

The causes and consequences of increasing West Nile virus activity in Europe

Eleni Patsoula (Athens, Greece)

Co-organised with: ESCMID Study Group for Public Health Microbiology (ESGPHM)

1-hour Symposium

Tuberculous meningitis

Diagnosis and treatment of TB meningitis: what's new?

Fiona Cresswell (Kampala, Uganda)

An update on the management of childhood TB meningitis

Ronald van Toorn (Cape Town, South Africa)

Co-organised with: Trainee Association of ESCMID (TAE) Steering Committee and European Society of Paediatric Infectious Diseases (ESPID)

1-hour Symposium

Pathogenic *Escherichia coli*: the emergence of cross-pathotypes from the genomic continuum

***E. coli* pathotypes causing paediatric infection in low resource settings**

Inacio Mandomando (Maputo, Mozambique)

Redefining enteroaggregative *Escherichia coli* (EAEC): genomic characterisation of epidemiological EAEC strains

Nadia Boisen (Copenhagen, Denmark)

1-hour Symposium

The changing picture of childhood pneumonia

Impact of COVID-19 pandemic on epidemiology of childhood pneumonia

Shabir Madhi (Randburg, South Africa)

Impact of the pandemic on PCV vaccination globally

TBA

Co-organised with: International Society of Pneumonia and Pneumococcal Diseases (ISPPD)

1-hour Symposium

Should you manage differently bloodstream infection in immunocompromised patients?

Rapid diagnostic testing: is it a life saver for immunocompromised patients?

Gian Maria Rossolini (Florence, Italy)

What is different in the treatment of immunocompromised patients

Maristela P. Freire (Sao Paulo, Brazil)

Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH)

Preliminary Programme

1-hour Symposia

1-hour Symposium

Updates on antimicrobial susceptibility testing of mycobacteria

Updates and open questions on the recently revised WHO critical concentrations for drug susceptibility testing of *Mycobacterium tuberculosis*
Claudio Köser (Cambridge, United Kingdom)
The EUCAST approach for drug susceptibility testing of mycobacteria: past, present, future
Emmanuelle Cambau (Paris, France)

Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) Antimicrobial Susceptibility Testing of Mycobacteria Subcommittee

1-hour Symposium

Does AMR mitigation in LMICs require technical capacity more than funding?

Building human technical capacity to mitigate AMR in LMICs
Mirfin Mpundu (Lusaka, Zambia)
Development funding is critical for the implementation of national action plans on AMR in LMICs
Haileyesus Getahun (Geneva, Switzerland)

Co-organised with: International Centre for Antimicrobial Resistance Solutions (ICARS) and World Health Organization (WHO)

1-hour Symposium

AMR crossroads between public health, planetary health, and the climate change crisis

Co-evolutionary governance of antibiotic resistance for global sustainability: pathways for public health and environmental stewardship
Peter Søgaard Jørgensen (Stockholm, Sweden)
Transmission of infectious diseases and antibiotic resistant bacteria in the environment resulting from human exposure
Marie-Cécile Ploy (Limoges, France)

Co-organised with: ESCMID Study Group for Public Health Microbiology (ESGPHM)

1-hour Symposium

mecC MRSA: Epidemiology and evolution

Natural reservoirs of *mecC* MRSA
Maria Carmen Torres (Logroño, Spain)
mecC MRSA in hedgehogs predates the antibiotic era
Jesper Larsen (Copenhagen, Denmark)

1-hour Symposium

Addressing global disparities in antibiotic stewardship: strengthening LMICs

Disparities and gaps for implementation of AMS in LMIC
Nusrat Shafiq (New Delhi, India)
Developing capacity for sustainable implementation of AMS programs in sub-Saharan countries
Kenneth Iregbu (Abuja, Nigeria)

1-hour Symposium

Beyond species ID: Innovative uses of MALDI-TOF in the clinical microbiology lab

MALDI-TOF for AMR detection and outbreak tracking in the hospital setting
Lucie Amoureux (Dijon, France)
Phenotype prediction using MALDI-TOF data and machine learning
Adrian Egli (Basel, Switzerland)

1-hour Symposium

Combination therapies: from models to patients

Favourable combination therapies: evidence from pre-clinical studies
Thomas Tängdén (Uppsala, Sweden)
Combination therapies in clinical trials: what is the evidence?
Dafna Yahav (Petah-Tikva, Israel)

1-hour Symposium

Top papers in mycology

Fungal pathogenesis and its application
Mihai Netea (Nijmegen, Netherlands)
Advances in treatment and drug susceptibility
Nelesh Govender (Johannesburg, South Africa)

1-hour Symposium

One health and mycology: what are the significant and potential interactions between agriculture and human health?

What is the evidence that agricultural azole use drives drug resistance in human fungal pathogens?
Paul Eduard Verweij (Nijmegen, Netherlands)
How can we minimise the risk of development of antifungal resistance in the environment?
Marin Brewer (Athens, United States)

Preliminary Programme

1-hour Symposia

1-hour Symposium

From pipeline into niche or daily practice? Emerging antifungals and fungal diagnostics

Where do novel antifungals fit in clinical practice?
Nina Khanna (Basel, Switzerland)

New fungal diagnostic tests to support the use of novel antifungal agents

Luis Ostrosky-Zeichner (Houston, United States)

Co-organised with: International Immunocompromised Host Society (ICHS)

1-hour Symposium

Invasive fungal diseases (IFDs) in young age: similarities and differences

Epidemiological trends of IFDs in neonates, children, and adolescents

Emmanuel Roilides (Thessaloniki, Greece)

Diagnostic difficulties in young IFD patients: biomarkers and imaging

Elio Castagnola (Genoa, Italy)

Co-organised with: ESCMID Fungal Infection Study Group (EFISG)

1-hour Symposium

Cutaneous leishmaniasis: a continuing challenge

Imported cutaneous leishmaniasis in migrants

Özgür Kurt (Istanbul, Turkey)

Cutaneous leishmaniasis in South America

Dalila Martinez (Lima, Peru)

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)

1-hour Symposium

Using water to monitor circulating pathogens

An interplay between antibiotic residues and antibiotic resistance genes in wastewater

Katariina MM Pärnänen (Helsinki, Finland)

Sewage surveillance of antibiotic resistance – a complement to traditional clinical surveillance

Joakim Larsson (Gothenburg, Sweden)

Co-organised with: ESCMID Study Group for Epidemiological Markers (ESGEM), ESCMID Food- and Water-Borne Infections Study Group (EFWISG)

1-hour Symposium

Dawn of the ticks - implications for Europe

Dynamics of the tick population within the UK

Jolyon Medlock (London, United Kingdom)

Changing patterns of tick-borne diseases in Europe

Philippe Parola (Marseille, France)

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)

1-hour Symposium

Clostridioides difficile infection: importance of learning from patients' experience

Letters from the Home Front: patient experiences of CDI and what they mean for CDI research

Jane Freeman (Leeds, United Kingdom)

Involving patients in research for better outcomes

Judith Strawbridge (Dublin, Ireland)

Co-organised with: ESCMID Study Group for *Clostridioides difficile* (ESGCD)

1-hour Symposium

Fighting biofilm with non-traditional antibacterials

Antisense therapy against biofilms

Nuno F. Azevedo (Porto, Portugal)

Phage-inspired leads for antibiotics

Rob Lavigne (Leuven, Belgium)

Co-organised with: ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA) and ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)

1-hour Symposium

Recent top papers in transplant ID and haem/onc ID

SOT-ID

David van Duin (Chapel Hill, United States)

haem/onc ID

Carlota Gudíol (Barcelona, Spain)

1-hour Symposium

AI in infectious disease management and control

Machine learning for improved diagnosis of infections

Melis Anahtar (Boston, United States)

AI for improved sepsis management

Paul Elbers (Amsterdam, Netherlands)

Co-organised with: Japanese Association Infectious Disease (JAID)

Preliminary Programme

1-hour Symposia

1-hour Symposium

COVID-19 beyond the clinic: the importance of public engagement

Public engagement in COVID-19: pros and cons from the front line

Yazdan Yazdanpanah (Paris, France)

Science, policy, and social media in COVID-19

Isabella Eckerle (Geneva, Switzerland)

Co-organised with: ESCMID Scientific Affairs Subcommittee

1-hour Symposium

Communicating COVID-19: fact and fiction

Online activity in 2020-2021: what happened, and who was active?

Francesco Gesualdo (Rome, Italy)

Communicating new vaccines: lessons learnt from listening online

Bea Rofagha (Brussels, Belgium)

Co-organised with: ESCMID Vaccine Study Group (EVASG)



Preliminary Programme

Meet-the-Expert Sessions

Meet-the-Expert Session

Hepatitis D virus: the neglected viral hepatitis

Cihan Yurdaydin (Istanbul, Turkey)
TBA

Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH) and European Society for Virology (ESV)

Meet-the-Expert Session

Diagnosis and treatment of herpes simplex encephalitis

Oguz Resat Sipahi (Izmir, Turkey)
Jean Paul Stahl (Grenoble, France)

Co-organised with: Infectious Diseases and Clinical Microbiology Specialty Society of Turkey (EKMUD)

Meet-the-Expert Session

EUCAST Frequently Asked Questions

Erika Matuschek (Växjö, Sweden)
Mandy Wootton (Cardiff, United Kingdom)

Co-organised with: European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee

Meet-the-Expert Session

ESCMID & IDSA treatment guidelines for MDR Gram-negative bacterial infections

Mical Paul (Haifa, Israel)
Pranita Tamma (Baltimore, United States)

Co-organised with: Infectious Diseases Society of America (IDSA)

Meet-the-Expert Session

Driving the response to EIDs in LMICs with genomics and bioinformatics

Christian Happi (Ede, Nigeria)
Alan Christoffels (Bellville, South Africa)

Meet-the-Expert Session

External Quality Assessment in microbial genomics

Aitana Lebrand (Geneva, Switzerland)
Denise O'Sullivan (Middlesex, United Kingdom)

Co-organised with: ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD) and ESCMID Study Group for Epidemiological Markers (ESGEM)

Meet-the-Expert Session

Controversial microbiology results in implant-related infections (IAI): how to handle them?

Hege Vangstein Aamot (Lørenskog, Norway)
Maria Eugenia Portillo (Pamplona, Spain)

Co-organised with: ESCMID Study Group for Implant-Associated Infections (ESGIAI)

Meet-the-Expert Session

How to apply Digital PCR in clinical microbiology

Jim Huggett (London, United Kingdom)
Keith Jerome (Seattle, United States)

Meet-the-Expert Session

Dosing regimens of fosfomycin and colistin: have we been dosing all wrong?

Fernando Docobo-Perez (Sevilla, Spain)
Lena Friberg (Uppsala, Sweden)

Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)

Meet-the-Expert Session

Reconciling sepsis initiatives and antimicrobial stewardship programs

Jeroen Schouten (Nijmegen, Netherlands)
Karin Thursky (Carlston, Australia)

Meet-the-Expert Session

Antimicrobial stewardship in the emergency department

Marlies Hulscher (Nijmegen, Netherlands)
Carlos Palos (Loures, Portugal)

Co-organised with: ESCMID Study Group for Antimicrobial Stewardship (ESGAP)

Preliminary Programme

Meet-the-Expert Sessions

Meet-the-Expert Session

Implementing PK/PD and TDM of anti-infectives in clinical practice

Sophie Stocker (Sydney, Australia)
Federico Pea (Bologna, Italy)

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

Meet-the-Expert Session

Duration of therapy: what we know and what we do

Angela Huttner (Geneva, Switzerland)
Jose Ramon Pano-Pardo (Zaragoza, Spain)

Co-organised with: Clinical Microbiology and Infection (CMI) Board of Editors

Meet-the-Expert Session

Azole resistant *Candida parapsilosis*: a new nosocomial threat?

Mariana Castanheira (Austin, United States)
TBA

Co-organised with: ESCMID Fungal Infection Study Group (EFISG)

Meet-the-Expert Session

Current approaches to prevent invasive fungal diseases in paediatric patients

Andreas Groll (Münster, Germany)
Maria Elena Santolaya (Santiago, Chile)

Co-organised with: ESCMID Fungal Infection Study Group (EFISG)

Meet-the-Expert Session

How I treat severe *Stenotrophomonas maltophilia* infections

Marco Falcone (Pisa, Italy)
David van Duin (Chapel Hill, United States)

Meet-the-Expert Session

Contact precautions and cleaning for MDR prevention

Stephanie Dancer (Glasgow, United Kingdom)
Gonzalo Bearman (Richmond, United States)

Co-organised with: EUCIC Steering Committee

Meet-the-Expert Session

How to do infection control, season 2: construction and renovation

Birgitta Lytsy (Uppsala, Sweden)
Elisabeth Presterl (Vienna, Austria)

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI)

Meet-the-Expert Session

FDG-PET/CT and outcome of infections in immunosuppressed patients

Nesrin Ghanem-Zoubi (Haifa, Israel)
TBA

Co-organised with: ESGICH and International Immunocompromised Host Society (ICHS)

Meet-the-Expert Session

Getting to yes: strengthening vaccine uptake in hard-to-reach and vaccine-hesitant communities

Sally Hargreaves (London, United Kingdom)
Isabelle Bonmarin (Saint-Maurice, France)

Co-organised with: ESCMID Study Group for Infections in Travellers and Migrants (ESGITM)

Meet-the-Expert Session

How I treat infections in patients awaiting solid organ transplantation

Margaret Hannan (Dublin, Ireland)
TBA

Co-organised with: European Association for the Study of the Liver (EASL), ESCMID Study Group for Infections in Compromised Hosts (ESGICH), and ESCMID Study Group for Anaerobic Infections (ESGAI)

Meet-the-Expert Session

Interactive paediatric cases

Julie Toubiana (Paris, France)
TBA

Co-organised with: European Society of Paediatric Infectious Diseases (ESPID)

Preliminary Programme

Meet-the-Expert Sessions

Meet-the-Expert Session

Antimicrobial resistance and COVID-19: increase or decrease?

Alison Helen Holmes (London, United Kingdom)
Jose Artur Paiva (Porto, Portugal)

Co-organised with: European Centre for Disease Prevention and Control (ECDC)

Meet-the-Expert Session

Nosocomial transmission of SARS-CoV2: have you looked at all the risks

Emine Alp Mese (Ankara, Turkey)
TBA

Co-organised with: ESCMID Study Group for Forensic and Postmortem Microbiology (ESGFOR), European Society of Pathology (ESP), and Spanish Society of Forensic Pathology (SEPAF)

Meet-the-Expert Session

How to harness Artificial Intelligence for vaccines: the COVID-19 example

Guillaume Beraud (Poitiers, France)
Carolina Garcia Vidal (Barcelona, Spain)

Co-organised with: ESCMID Vaccine Study Group (EVASG)

Preliminary Programme

2-hour Educational Workshops

2-hour Educational Workshop

The different faces of Lyme borreliosis

In the skin: dermatologic manifestations of Lyme borreliosis

Franc Strle (Ljubljana, Slovenia)

In the brain: Lyme neuroborreliosis

Randi Eikeland (Kristiansand, Norway)

In the joints: Lyme arthritis

Benoît Jaulhac (Strasbourg, France)

Co-organised with: ESCMID Study Group for Lyme Borreliosis (ESGBOR)

2-hour Educational Workshop

Subacute and chronic meningitis

Infectious causes of chronic meningitis: diagnostic considerations and workup

Bettina Pfausler (Innsbruck, Austria)

Non-infectious differential diagnosis in patients with sub-acute and chronic meningitis

Uta Meyding-Lamade (Frankfurt, Germany)

Post-Lyme disease syndrome:

what is it and how to deal with it?

Randi Eikeland (Kristiansand, Norway)

Co-organised with: The Collaborative on Fatigue Following Infection (COFFI) and ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)

2-hour Educational Workshop

What is new in nocardiosis?

Challenges in susceptibility testing of *Nocardia*

Barbara Brown-Elliott (Houston, United States)

Risk factors among susceptible populations:

is there a role for prophylaxis?

David Lebeaux (Paris, France)

Tailor-made treatment regimens for nocardiosis: can imaging and other clinical markers guide therapeutic decision making?

Ili Margalit (Petah-Tikva, Israel)

2-hour Educational Workshop

How to use intervention and implementation research to mitigate AMR

Intervention, operational, and implementation research: key constructs

Sabiha Essack (Durban, South Africa)

Developing an implementation research roadmap (2 x 5–10-minute introduction to session)

Alex Costa (New York, United States)

Co-organised with: International Centre for Antimicrobial Resistance Solutions (ICARS)

2-hour Educational Workshop

Novel predictive and diagnostic tools in severe viral and bacterial infections

Living colours of infection and inflammation

Olivier Gheysens (Brussels, Belgium)

Hypercytokinaemia in critically ill COVID-19 as indicator of cell death and secondary bacterial infections

Srikanth Mairpady Shambat (Zurich, Switzerland)

Specific clinical phenotypes of necrotising soft-tissue infection predicted by discriminatory biomarker signatures

Anna Norrby-Teglund (Huddinge, Sweden)

2-hour Educational Workshop

Behavioural science essentials for antimicrobial stewards

Antibiotic prescribing as a decision-making process

Sara Cosgrove (Baltimore, United States)

A behavioural analysis of antibiotic prescribing

Susan Michie (London, United Kingdom)

Choosing and implementing interventions to modify prescribing behaviour

TBA

2-hour Educational Workshop

Optimising the use of antibiotics for neonates and children

Antibiotic use and stewardship in the PICU

TBA

Antibiotic use and stewardship in the NICU

Angelika Berger (Vienna, Austria)

Surgical prophylaxis in neonates and children

Elio Castagnola (Genoa, Italy)

Hanna Renk (Tübingen, Germany)

2-hour Educational Workshop

Don't get lost in translation: the use of preclinical PK/PD models in anti-infective drug development

The role of *in vitro* models

Alasdair Mc Gowan (Bristol, United Kingdom)

The role of *in vivo* models

William Couet (Poitiers, France)

The role of *in silico* models

Elisabeth Nielsen (Uppsala, Sweden)

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

Preliminary Programme

2-hour Educational Workshops

2-hour Educational Workshop

Fungal diagnosis: questions from the bedside and answers from the bench

Fungal infections, not just in neutropaenia

Dimitrios Kontoyiannis (Houston, United States)

Role of pathogen and host pathophysiology in fungal diagnosis

Cristina Cunha (Braga, Portugal)

Guidance from the bench: human and fungal markers

Katrien Lagrou (Leuven, Belgium)

2-hour Educational Workshop

Antifungal prophylaxis in transplantation: a benefit for which patient?

Fungal infection in transplant patients: where are we now?

Maja Weisser (Basel, Switzerland)

Universal vs patient risk driven prophylaxis in lung transplant recipients

Shahid Hussein (Toronto, Canada)

Perspectives for the improved management of invasive mould infections

TBA

Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH) and International Immunocompromised Host Society (ICHS)

2-hour Educational Workshop

Transdisciplinary approach to Global Health: the case of neglected tropical diseases

One Health approach for NTD control programmes

Bernadette Abela-Ridder (Lausanne, Switzerland)

Novel approaches to screening for neglected tropical diseases in migrants

Emmanuel Bottieau (Antwerpen, Belgium)

New therapeutic approaches to neglected tropical diseases

Zeno Bisoffi (Verona, Italy)

Co-organised with: ESCMID Study Group for Infections in Travellers and Migrants (ESGIM)

2-hour Educational Workshop

Changing world of infectious diseases: urbanisation and digitalisation

Infectious diseases and globalised urbanisation

TBA

Implementing an innovative integrated multi-infection screening digital decision support tool (IS-MiHealth)

Ana Requena-Méndez (Stockholm, Sweden)

Health Catch-UP!: digital innovations to strengthen multi-disease screening and catch-up vaccination in at-risk migrants

Jessica Carter (London, United Kingdom)

Co-organised with: ESCMID Study Group for Infections in Travellers and Migrants (ESGIM) and ESCMID International Affairs Subcommittee (EIAS)

2-hour Educational Workshop

New perspectives on Schistosomiasis in Europe

Gaps in management of Schistosomiasis in Europe

Eyrun Floercke Kjetland (Oslo, Norway)

One Health perspective on Schistosomiasis: prevalence and distribution of schistosomiasis in a multi-host system

Joanne P Webster (London, United Kingdom)

Early lab diagnosis of schistosomiasis: your lab's wish list

TBA

Co-organiser: ESCMID Study Group for Clinical Parasitology (ESGCP)

2-hour Educational Workshop

How to make clinical trials more efficient

Which operational factors determine the efficiency of clinical trial execution

Marouan Zarrouk (Cologne, Germany)

Which design aspects can enhance clinical trial efficiency

Marlieke de Kraker (Geneva, Switzerland)

What is an adaptive platform trial

Cornelis H. van Werkhoven (Utrecht, Netherlands)

Co-organised with: European Clinical Research Alliance on Infectious Diseases (ECRAID)

Preliminary Programme

2-hour Educational Workshops

2-hour Educational Workshop

Advances in *Clostridioides difficile* infection outbreak prevention and control

Is there a role for ribotyping in the WGS era?

Windy Tanner (New Haven, United States)

Any *Clostridium* lurking in your patient's room?

The role of the environment and hospital infrastructure in *C. difficile* outbreaks

TBA

Going with the FLO: frontline ownership is crucial for

C. difficile outbreak prevention and management

Gianluca Ianiro (Rome, Italy)

Co-organised with: ESCMID Study Group for

Clostridioides difficile (ESGCD) and ESCMID Study Group

for Nosocomial Infections (ESGNI)

2-hour Educational Workshop

Prevention of nosocomial bloodstream infections

Epidemiology and impact of healthcare-associated BSI

Alessandro Cassini (Geneva, Switzerland)

CLABSI: successes and challenges

Debby Ben David (Holon, Israel)

Beyond the ICU: preventing nosocomial BSI hospital-wide

Jean-Christophe Lucet (Paris, France)

Co-organised with: ESCMID Study Group for Critically Ill

Patients (ESGCIP)

2-hour Educational Workshop

Infectious biofilm in the healthcare environment

Endoscope contamination: why does this happen and how can it be detected?

Michelle Alfa (Winnipeg, Canada)

Water-associated biofilms in the healthcare environment

TBA

Environmental reservoirs of infectious biofilm

Karen Vickery (Sydney, Australia)

Co-organised with: ESCMID Study Group for Biofilms

(ESGB) and European Study Group for Nosocomial Infections (ESGNI)

2-hour Educational Workshop

The quest for reliable biofilm models: how to narrow the gap to clinical implementation?

Real-time monitoring of biofilms using confocal microscopy

Mathias Mücken (Braunschweig, Germany)

Bacterial infection models based on organoid cell cultures

Helle Krogh Johansen (Copenhagen, Denmark)

In vivo models: studying soft tissue infection

Kendra Rumbaugh (Lubbock, United States)

Co-organised with: ESCMID Study Group for Biofilms (ESGB)

2-hour Educational Workshop

Antimicrobial tolerance in pathogens: bench to bedside

Bacterial replication and bioenergetics in antibiotic lethality and treatment-shortening activity

Martin Voskuil (Aurora, United States)

Mechanisms of antimicrobial tolerance

TBA

Clinical implications of tolerance

Jacob Strahilevitz (Jerusalem, Israel)

2-hour Educational Workshop

Opportunistic infections of the central nervous system

Suspecting CNS infection in haemato-oncology patients

Jacob Bodilsen (Aalborg, Denmark)

Infections of the CNS in solid organ transplant patients

Judith Anesi (Philadelphia, United States)

Fungal CNS infections in immunocompromised patients

Stefan Schwartz (Berlin, Germany)

Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)

2-hour Educational Workshop

Getting your CM/ID paper published

Being an author - how to write scientific articles

Jesus Rodríguez Bano (Seville, Spain)

Being a peer-reviewer - how to perform reviews

Mariska Mg Leeflang (Amsterdam, Netherlands)

The editor's view

Leonard Leibovici (Petah-Tiqva, Israel)

Co-organised with: Clinical Microbiology and Infection (CMI) Board of Editors

Preliminary Programme

2-hour Educational Workshops

2-hour Educational Workshop

Should economical aspects be considered for CM/ID/ICP guidelines?

The current state of inclusion of economic issues in infectious disease guidelines

Ravi Jhaveri (Chicago, United States)

Pro (considering economic aspects for guideline development)

Joost Hopman (Nijmegen, Netherlands)

Con (considering economic aspects for guideline development)

Benedikt Huttner (Geneva, Switzerland)

Co-organised with: ESCMID Guideline Subcommittee

2-hour Educational Workshop

Overcoming methodological challenges in CM/ID studies

Making the most out of before-after studies: when life gives you lemons

TBA

Confounding the confounders: methods to correct for confounding in etiological studies

TBA

Time matters! State-of-the-art methods to analyse clinical data

Martin Wolkewitz (Freiburg, Germany)

Co-organised with: Trainee Association of ESCMID (TAE) Steering Committee and ESCMID Education Subcommittee

2-hour Educational Workshop

COVID-19 and consequences for mental health from different perspectives

COVID-19 pandemic impact on clinicians' mental health and wellbeing

Gregory Keane (Paris, France)

Role of trainees during the pandemic and consequences for their wellbeing

TBA

Impact of the COVID-19 pandemic on the mental health and wellbeing of patients

TBA

2-hour Educational Workshop

Understanding COVID-19 lung disease

Infectious disease and public health perspective

Raquel Duarte (Porto, Portugal)

ICU perspective

TBA

Pathologist's perspective

TBA

Co-organised with: ESCMID Study Group for Forensic and Postmortem Microbiology (ESGFOR), Spanish Society of Forensic Pathologists, and Spanish Society of Pathology (SEAP)

2-hour Educational Workshop

COVID-19 vaccination of special populations: protecting the vulnerable

Vaccinating immunocompromised individuals

Aruna Subramanian (Stanford, United States)

Vaccinating individuals with underlying medical conditions associated with high risk for severe COVID-19

Jamie Lopez Bernal (London, United Kingdom)

TBA

Vaccination of infants and children, and of pregnant women

TBA

Co-organised with: ESCMID Vaccine Study Group (EVASG), Professional Affairs Subcommittee, and International Affairs

Preliminary Programme

3-hour Educational Workshops

3-hour Educational Workshop

EUCAST Educational Workshop

EUCAST Update

Christian Giske (Stockholm, Sweden)

Putting certainty into antimicrobial susceptibility testing

Gunnar Kahlmeter (Växjö, Sweden)

PK/PD breakpoints in the EUCAST breakpoint tables

Shampa Das (Liverpool, United Kingdom)

Revising aminopenicillin breakpoints

John Turnidge (Adelaide, Australia)

Screening and testing for antifungal resistance

Maiken Cavling Arendrup (Copenhagen, Denmark)

Co-organised with: European Committee on Antimicrobial Susceptibility Testing (EUCAST) and ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)



Preliminary Programme

Year in Symposia

Year in Clinical Microbiology

Brigitte Lamy (Nice, France)
Veroniek Saegeman (Sint-Niklaas, Belgium)

Year in Infectious Diseases

Elena Carrara (Verona, Italy)
TBA

Year in Infection Control

Stephanie J. Dancer (Glasgow, United Kingdom)
Esther Calbo (Barcelona, Spain)